Search results for "Socio-culturale"

showing 10 items of 201 documents

The evolution and changing ecology of the African hominid oral microbiome

2021

Significance The microbiome plays key roles in human health, but little is known about its evolution. We investigate the evolutionary history of the African hominid oral microbiome by analyzing dental biofilms of humans and Neanderthals spanning the past 100,000 years and comparing them with those of chimpanzees, gorillas, and howler monkeys. We identify 10 core bacterial genera that have been maintained within the human lineage and play key biofilm structural roles. However, many remain understudied and unnamed. We find major taxonomic and functional differences between the oral microbiomes of Homo and chimpanzees but a high degree of similarity between Neanderthals and modern humans, incl…

Neanderthalbindinggut microbiomemicrobiomeprimatePrehistòriaNeanderthalEvolutionsbiologiPrimatesalivary amylasePhylogeny0303 health sciencesMultidisciplinaryEcologyGeographybiologyEcologyMicrobiotaHuman microbiomeancientHominidae402SH6_2Biological SciencesBiological Evolutiongenomes suggestHuman evolution[SDE]Environmental SciencesOral MicrobiomeR-packagePan troglodytesdental plaque[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and PrehistoryEcology (disciplines)Socio-culturaleMicrobiologysalivary alpha-amylase03 medical and health sciencesbiology.animalDental calculus; microbiome; Neanderthal; primate; salivary amylaseAnimalsHumansMicrobiomevisualization030304 developmental biologyMouthperiodontal-diseaseEvolutionary BiologyGorilla gorillaBacteria030306 microbiologydental calculusDNAMikrobiologiBiofilmsFOS: Biological sciencesAnthropologyAfricaUpper PaleolithicMetagenome
researchProduct

Search for the dark photon in π0 decays

2015

A sample of $1.69\times 10^7$ fully reconstructed $\pi^0\to\gamma e^+e^-$ decay candidates collected by the NA48/2 experiment at CERN in 2003--2004 is analysed to search for the dark photon ($A'$) production in the $\pi^0\to\gamma A'$ decay followed by the prompt $A'\to e^+e^-$ decay. No signal is observed, and an exclusion region in the plane of the dark photon mass $m_{A'}$ and mixing parameter $\varepsilon^2$ is established. The obtained upper limits on $\varepsilon^2$ are more stringent than the previous limits in the mass range $9~{\rm MeV}/c^2<m_{A'}<70~{\rm MeV}/c^2$. The NA48/2 sensitivity to the dark photon production in the $K^\pm\to\pi^\pm A'$ decay is also evaluated.

Nuclear and High Energy PhysicsDark matterKAON DECAYSSocio-culturaleAstronomy & Astrophysics01 natural sciencesDark photondark matterHigh Energy Physics - ExperimentPhysics Particles & FieldsNuclear physics0202 Atomic Molecular Nuclear Particle And Plasma Physics0103 physical sciencesdark matter meson decays010306 general physicsDETECTORPhysicsNuclear and High Energy Physics dark photon photon pion neutral pionneutral pionRange (particle radiation)Large Hadron ColliderScience & Technology010308 nuclear & particles physicsPhysicsphotonDark Photon; KAON DECAYSpionmeson decaysNuclear & Particles Physicslcsh:QC1-999Physics NuclearPhysical Sciencesdark photonFotoneHigh Energy Physics::ExperimentParticle Physics - Experimentlcsh:PhysicsHigh Energy Physics - Experiment; Dark Photon
researchProduct

Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference

2019

Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines- are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these t…

OncologyMaleSurvival030232 urology & nephrologyDiseaseCarcinoma; Community network; Europe; Germ cell and embryonal; Neoplasms; Penis neoplasms; Rare diseases; Squamous cell; Survival; Tertiary care centres; Testicular neoplasms; Surgery; Oncology0302 clinical medicineNeoplasmsEpidemiologyTesticular neoplasmReferral and ConsultationPenis neoplasmsCarcinoma ; Community network ; Europe ; Germ cell and embryonal ; Neoplasms ; Penis neoplasms ; Rare diseases ; Squamous cell ; Survival ; Tertiary care centres ; Testicular neoplasmsGeneral MedicineNeoplasms Germ Cell and EmbryonalTertiary care centreRare diseasesSurvival RateEuropeOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellHumanmedicine.medical_specialtyTesticular neoplasmsPenile squamous cell carcinomaGerm cell and embryonalCommunity networkSocio-culturaleCancer Care FacilitiesTertiary care centres03 medical and health sciencesPenis neoplasmRare DiseaseInternal medicinemedicineCarcinomaHumansPenile NeoplasmsNeoplasm StagingPenis Neoplasmsbusiness.industryCancer Care FacilitieSquamous cellCarcinomaLymphatic Metastasimedicine.diseaseTesticular germ cellAdult lifePenile NeoplasmProper treatmentNeoplasmLymph Node ExcisionSurgerybusinessDelivery of Health Care
researchProduct

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a r…

2018

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely remov…

OncologyReceptor ErbB-2Settore MED/06 - Oncologia Medicaletrozolelaw.inventionAdjuvant anastrozolechemistry.chemical_compound0302 clinical medicineRandomized controlled trialExemestanelawAdjuvant anastrozole; exemestane; letrozole; tamoxifen; breast cancerAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicinetamoxifenAromatase InhibitorsLetrozoleHazard ratioMiddle AgedReceptors EstrogenTolerabilityOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleReceptors ProgesteroneBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtySocio-culturaleAnastrozoleBreast NeoplasmsAnastrozoleDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineAromatase InhibitorHumansAgedAntineoplastic Combined Chemotherapy ProtocolAndrostadienebusiness.industrymedicine.diseaseAndrostadieneschemistrybusinessexemestaneTamoxifen
researchProduct

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Methods The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. Results A total of 1244 patients were included. Compared to anatomic stage, the prognost…

OncologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentlcsh:MedicineAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy Protocols8th AJCC030212 general & internal medicineStage (cooking)8th AJCC; Breast cancer; HER2-positive; Prognostic stage; TrastuzumabGeneral MedicineMiddle AgedPrognosisImmunologicalLocal030220 oncology & carcinogenesisFemaleResearch Articlemedicine.drugAdultmedicine.medical_specialtyRandomizationSocio-culturaleAntineoplastic AgentsBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancerInternal medicinePrognostic stagemedicineAdjuvant therapyHumanserbB-2AgedNeoplasm StagingCancer stagingChemotherapybusiness.industrylcsh:RCancerGenes erbB-2Trastuzumabmedicine.diseaseHER2-positive Breast cancer Trastuzumab Prognostic stage 8th AJCCHER2-positiveNeoplasm RecurrenceGenesNeoplasm Recurrence Localbusiness
researchProduct

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

2018

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT&gt;2 cm, G3, lympho-vascular invasion, Ki-67 &gt; 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…

OncologyTime FactorsAdjuvant Breast cancer Cardiac safety De-escalated treatment TrastuzumabSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentAnthracycline030204 cardiovascular system & hematologyBreast cancerAntineoplastic Agents ImmunologicalErbB-20302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsClinical endpointAnthracyclinesskin and connective tissue diseasesAdjuvantMastectomyAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab;Hazard ratioHematologyMiddle AgedChemotherapy regimenBridged-Ring CompoundImmunologicalLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleTaxoidsTrastuzumab adjuvant breast cancer cardiac safety de-escalated treatmentBreast NeoplasmMastectomyHumanReceptormedicine.drugAdultBridged-Ring Compoundsmedicine.medical_specialtyTime FactorSocio-culturaleBreast NeoplasmsAntineoplastic AgentsDe-escalated treatmentDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerTaxoidInternal medicinemedicineHumansChemotherapyRisk factorAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy ProtocolCardiac safetybusiness.industryTrastuzumabAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab; Hematology; Oncologymedicine.diseaseCardiotoxicityNeoplasm RecurrenceNeoplasm Recurrence LocalbusinessAnnals of Oncology
researchProduct

Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium

2015

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; The role of mitogen-activated protein kinases (MAPK) in regulating the inflammatory response in the airways of patients with chronic obstructive pulmonary disease (COPD) and asthmatic patients is unclear. &lt;b&gt;&lt;i&gt;Objectives:&lt;/i&gt;&lt;/b&gt; To investigate the expression of activated MAPK in lungs of COPD patients and in bronchial biopsies of asthmatic patients and to study MAPK expression in bronchial epithelial cells in response to oxidative and inflammatory stimuli. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Immunohistochemical expression of phospho (p)-p38 MAPK, p-JNK1 and p-ERK1/2 was measured in bronchial mucosa in pat…

P38 MAPKMaleMAPK/ERK pathwayAsthma phenotypeSMOKERespiratory SystemMitogen-activated protein kinases; p65; Pathology of chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease phenotypes; Asthma phenotypesPathology of chronic obstructive pulmonary diseasep38 Mitogen-Activated Protein KinasesChronic obstructive pulmonary disease phenotypePulmonary Disease Chronic ObstructiveOXIDATIVE STRESSMACROPHAGESRespiratory systemMitogen-activated protein kinasesChronic obstructive pulmonary disease phenotypesMitogen-activated protein kinases; p65; pathology of chronic obstructive pulmonary disease phenotypes; asthma phenotypesCOPDp65KinaseAsthma phenotypes; Chronic obstructive pulmonary disease phenotypes; Mitogen-activated protein kinases; p65; Pathology of chronic obstructive pulmonary disease; Pulmonary and Respiratory MedicineACTIVATED PROTEIN-KINASEInterleukinMiddle AgedImmunohistochemistrypathology of chronic obstructive pulmonary disease phenotypesAsthma phenotypesFemaleLife Sciences & BiomedicinePulmonary and Respiratory Medicinep38 mitogen-activated protein kinasesBlotting WesternINHIBITIONSocio-culturaleBronchiRespiratory MucosaOBSTRUCTIVE PULMONARY-DISEASE1102 Cardiovascular Medicine And HaematologyCell LinemedicineHumansLymphocyte CountInterleukin 8AgedAsthmaScience & Technologybusiness.industryInterleukin-8Transcription Factor RelAPATHWAYSMitogen-activated protein kinasemedicine.diseaseAsthmarespiratory tract diseasesSEVERITYCase-Control StudiesCELLSImmunologybusiness
researchProduct

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

2016

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care p…

PediatricsAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis; Immunology and AllergyIMPACTHay feverRespiratory Medicine and AllergyDiseaseReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineQUALITY-OF-LIFEHDE ALERHealth careMedicine and Health SciencesPERSISTENT ALLERGIC RHINITISMedicineImmunology and Allergy030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyAIRWAYS ICPComputingMilieux_MISCELLANEOUSRhinitiAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; RhinitisLungmedicin och allergiRhinitisPublic Health Global Health Social Medicine and Epidemiology3. Good healthREAL-LIFEAIRWAYS ICPsARIA; Rhinitis; ICT; EIP on AHA; Mobile technology; AIRWAYS ICPsHay feverCLINICAL-PRACTICE GUIDELINESHEALTHPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAEUROPEAN INNOVATION PARTNERSHIPImmunologySocio-culturaleClinical decision support systemICT; EIP on AHAPredictive medicine03 medical and health sciencesQuality of life (healthcare)Mobile technologyJournal ArticleMobile technologyAsmaAsthmaScience & TechnologyARIAbusiness.industryAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis;Settore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSCorrectionmedicine.disease2008 UPDATEFebre del fencAsthmaFolkhälsovetenskap global hälsa socialmedicin och epidemiologi030228 respiratory systemFamily medicineICTVISUAL ANALOG SCALEbusiness
researchProduct

Pregnancy e-health: a multicenter Italian cross-sectional study on internet use and decision-making among pregnant women

2013

Background Our study aimed to estimate the prevalence of pregnancy e-health seekers in a large Italian sample; to explore the factors influencing the choices of the childbearing women regarding their lifestyles after internet consultation; and finally to investigate potential differences between primiparous and multiparous women in internet use to find information about pregnancy. Methods A multicentre survey was carried out in seven Italian cities. Data were collected through a validated questionnaire administered in waiting rooms of outpatient departments by medical doctors. Respondents were questioned about their sociodemographic status, their use of the internet to seek pregnancy inform…

PediatricsGynaecology; Health Promotion; Maternal HealthCross-sectional studypregnancy e-healthstudy internetEpidemiologyMaternal HealthHealth BehaviorLogistic regressionChoice BehaviorGynaecologySeekersPregnancySurveys and QuestionnairesEpidemiologyPrevalenceMedicinehealthTelemedicineParityItalyThe InternetFemalePublic HealthAdultmedicine.medical_specialtyAdolescentDecision MakingInformation Seeking BehaviorSocio-culturaleHealth PromotionInterviews as TopicYoung AdultHumansLife StyleSettore MED/42 - IGIENE GENERALE E APPLICATAPregnancypregnancy; healthInternetDescriptive statisticsConsumer Health Informationbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseHealth promotionCross-Sectional StudiesLogistic ModelsFamily medicineMultivariate AnalysisEpidemiology; Public Health Environmental and Occupational HealthPregnant Womenbusiness
researchProduct

PURA- Related Developmental and Epileptic Encephalopathy: Phenotypic and Genotypic Spectrum

2021

Background and ObjectivesPurine-rich element-binding protein A (PURA) gene encodes Pur-α, a conserved protein essential for normal postnatal brain development. Recently, a PURA syndrome characterized by intellectual disability, hypotonia, epilepsy, and dysmorphic features was suggested. The aim of this study was to define and expand the phenotypic spectrum of PURA syndrome by collecting data, including EEG, from a large cohort of affected patients.MethodsData on unpublished and published cases were collected through the PURA Syndrome Foundation and the literature. Data on clinical, genetic, neuroimaging, and neurophysiologic features were obtained.ResultsA cohort of 142 patients was include…

Pediatricsmedicine.medical_specialtySocio-culturale[SDV.GEN] Life Sciences [q-bio]/GeneticsElectroencephalographyEpilepsyDevelopmental and Epileptic EncephalopathyIntellectual disabilitymedicineGenetics (clinical)feeding difficulties[SDV.GEN]Life Sciences [q-bio]/Geneticsmedicine.diagnostic_testbusiness.industryfungimedicine.diseaseHypotoniaEpileptic spasmsNeonatal hypotonianeonatal hypotoniaEpilepsy syndromesCohortepilepsyNeurology (clinical)medicine.symptombusiness
researchProduct